CoChat

Results of phase 3 of the CATIE schizophrenia trial

Open access
Stroup, T. Scott, Lieberman, Jeffrey A., McEvoy, Joseph P., Davis, Sonia M., Swartz, Marvin S., Keefe, Richard S.E., Miller, Alexander L., Rosenheck, Robert A., Hsiao, John K. · 2009 · Schizophrenia Research
Cited by 141

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Objective The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study examined the comparative effectiveness of antipsychotic treatments for individuals with chronic schizophrenia. Patients who had discontinued antipsychotic treatment in phases 1 and 2 were eligible for phase 3, in which they selected one of nine antipsychotic regimens with the help of their study doctor. We describe the characteristics of the patients who selected each treatment option and their outcomes. Method Two hundred and seventy patients entered phase 3. The open-label treatment options were monotherapy with oral aripiprazole, clozapine, olanzapine, perphenazine, quetiapine, risperidone, ziprasidone, long-acting injectable fluphenazine decanoate, or a combination of any two of these treatments. Results Few patients selected fluphenazine decanoate (n=9) or perphenazine (n=4). Similar numbers selected each of the other options (range 33–41). Of the seven common choices, those who selected clozapine and combination antipsychotic treatment were the most symptomatic, and those who selected aripiprazole and ziprasidone had the highest body mass index. Symptoms improved for all groups, although the improvements were modest for the groups starting with relatively mild levels of symptoms. Side effect profiles of the medications varied considerably but medication discontinuations due to intolerability were rare (7% overall). Conclusions Patients and their doctors made treatment selections based on clinical factors, including severity of symptoms, response to prior treatments, and physical health status. Fluphenazine decanoate was rarely used among those with evidence of treatment non-adherence and clozapine was underutilized for those with poor previous response. Combination antipsychotic treatment warrants further study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.schres.2008.10.011

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 141

Metadata

Authors
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Davis, S. M., Swartz, M. S., Keefe, R. S. E., Miller, A. L., Rosenheck, R. A., & Hsiao, J. K.
Venue
Schizophrenia Research
Publisher
Elsevier BV
Published
2009-01
Volume
107
Issue
1
Pages
1-12
ISSN
0920-9964 (ISSN-L)
OpenAlex
W2102868524
Cited by
141
References
1
FWCI
8.15
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Results of phase 3 of the CATIE schizophrenia trial. https://app.cochat.ai/papers/10.1016/j.schres.2008.10.011
The paper
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Davis, S. M., Swartz, M. S., Keefe, R. S. E., Miller, A. L., Rosenheck, R. A., & Hsiao, J. K. (2009). Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research. https://doi.org/10.1016/j.schres.2008.10.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.